NBM Business Summary

NatureWise Biotech & Medicals Corporation (NBM) is a Taiwan-based biotechnology firm specializing in the research, development, and commercialization of botanical-based therapeutic drugs and high-end nutraceuticals. The company generates revenue through a dual-track model: the sale of proprietary health supplements and the clinical development of small-molecule chemical drugs for licensing or future commercialization. Its primary business is divided into the Therapeutic Drug segment, centered on its lead oncology candidate NBM-BMX—a histone deacetylase (HDAC) inhibitor currently in Phase Ib/II trials for glioblastoma—and the Nutraceutical segment, which markets established products such as LipoCol Forte for cholesterol management and PPLs Taiwan Green Propolis. Within the Taiwanese biotech landscape, NBM competes with firms like Level Biotechnology, Meribank Biotech, and BioLASCO Taiwan, positioning itself as a niche innovator that bridges traditional botanical medicine with modern molecular oncology. NBM is led by Chairman and President Zhong Yang Huang (also known as Chung-Yang Huang), who has overseen the company’s strategic shift toward high-value drug development since its founding in 1990. The executive leadership team includes Jun Kai Chen, who serves as Chief Financial Officer and Assistant Vice President, and Xing Ling Cai, the Marketing Manager responsible for the company's nutraceutical distribution networks. The board of directors was recently strengthened in February 2026 with the appointment of Chang-Jun Ko as an Independent Director, reflecting a push toward enhanced corporate governance as the company advances its clinical pipeline. NBM’s leadership is characterized by a long-tenured management core that emphasizes the integration of audit-driven financial discipline, managed by Treasurer and Audit Office Manager Nian Ci Hong, with aggressive R&D investment in the global oncology market.